nach oben

Journal of Cancer Research and Clinical Oncology

Erschienen in:

01.07.2015 | Review – Clinical Oncology

T-cell-associated cellular immunotherapy for lung cancer

verfasst von: Ke Li, Qing Zhang, Yang Zhang, Jie Yang, Junnian Zheng

Erschienen in: Journal of Cancer Research and Clinical Oncology | Ausgabe 7/2015

Einloggen, um Zugang zu erhalten

Abstract

Purpose

The aim of the present study was to discuss recent findings on the role of T cells in lung cancer to provide information on their potential application, especially in cellular immunotherapy.

Methods

Data on the different types of T cells that are currently used for the treatment of lung cancer were obtained by searching the PUBMED database.

Results

Cytotoxic T lymphocytes, natural killer T cells, γδ T cells, lymphokine-activated killer cells, tumor-infiltrating lymphocytes, cytokine-induced killer cells and gene-modified T cells were analyzed to determine the benefits and drawbacks of their application in the treatment of lung cancer. Advances in the study of their antitumor mechanisms and directions for future research were discussed.

Conclusions

T cells are critical for tumorigenesis and therefore important targets for the treatment of lung cancer. T-cell-associated cellular immunotherapy opens up a window of opportunity for the development of complementary methods to traditional lung cancer treatments, which warrants further investigation to improve the clinical outcomes of lung cancer patients.

Aerts JG, Hegmans JP (2013) Tumor-specific cytotoxic T cells are crucial for efficacy of immunomodulatory antibodies in patients with lung cancer. Cancer Res 73:2381–2388CrossRefPubMed

Atkins MB, Lotze MT, Dutcher JP, Fisher RI, Weiss G, Margolin K, Abrams J, Sznol M, Parkinson D, Hawkins M, Paradise C, Kunkel L, Rosenberg SA (1999) High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 17:2105–2116PubMed

Atkins MB, Kunkel L, Sznol M, Rosenberg SA (2000) High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: long-term survival update. Cancer J Sci Am 6(Suppl 1):S11–S14PubMed

Baba T, Hanagiri T, Ichiki Y, Kuroda K, Shigematsu Y, Mizukami M, Sugaya M, Takenoyama M, Sugio K, Yasumoto K (2007) Lack and restoration of sensitivity of lung cancer cells to cellular attack with special reference to expression of human leukocyte antigen class I and/or major histocompatibility complex class I chain related molecules A/B. Cancer Sci 98:1795–1802CrossRefPubMed

Baba T, Hanagiri T, Takenoyama M, Shiota H, Kuroda K, Shigematsu Y, Ichiki Y, Uramoto H, So T, Yasumoto K (2010) Identification of a lung cancer antigen evading CTL attack due to loss of human leukocyte antigen (HLA) class I expression. Cancer Sci 101:2115–2120CrossRefPubMed

Brandes M, Willimann K, Bioley G, Levy N, Eberl M, Luo M, Tampe R, Levy F, Romero P, Moser B (2009) Cross-presenting human gammadelta T cells induce robust CD8+ alphabeta T cell responses. Proc Natl Acad Sci USA 106:2307–2312CrossRefPubMedCentralPubMed

Burjanadze M, Condomines M, Reme T, Quittet P, Latry P, Lugagne C, Romagne F, Morel Y, Rossi JF, Klein B, Lu ZY (2007) In vitro expansion of gamma delta T cells with anti-myeloma cell activity by Phosphostim and IL-2 in patients with multiple myeloma. Br J Haematol 139:206–216CrossRefPubMed

Cioffi M, Dorado J, Baeuerle PA, Heeschen C (2012) EpCAM/CD3-Bispecific T-cell engaging antibody MT110 eliminates primary human pancreatic cancer stem cells. Clin Cancer Res 18:465–474CrossRefPubMed

Couzin-Frankel J (2013) Breakthrough of the year 2013. Cancer Immunother Sci 342:1432–1433

Cui Y, Yang X, Zhu W, Li J, Wu X, Pang Y (2013) Immune response, clinical outcome and safety of dendritic cell vaccine in combination with cytokine-induced killer cell therapy in cancer patients. Oncol Lett 6:537–541PubMedCentralPubMed

Fiedler LR, Eble JA (2009) Decorin regulates endothelial cell-matrix interactions during angiogenesis. Cell Adhes Migr 3:3–6CrossRef

Fujii SI, Shimizu K, Okamoto Y, Kunii N, Nakayama T, Motohashi S, Taniguchi M (2013) NKT cells as an ideal anti-tumor immunotherapeutic. Front Immunol 4:409CrossRefPubMedCentralPubMed

Fukuyama T, Hanagiri T, Takenoyama M, Ichiki Y, Mizukami M, So T, Sugaya M, Sugio K, Yasumoto K (2006) Identification of a new cancer/germline gene, KK-LC-1, encoding an antigen recognized by autologous CTL induced on human lung adenocarcinoma. Cancer Res 66:4922–4928CrossRefPubMed

Goff SL, Smith FO, Klapper JA, Sherry R, Wunderlich JR, Steinberg SM, White D, Rosenberg SA, Dudley ME, Yang JC (2010) Tumor infiltrating lymphocyte therapy for metastatic melanoma: analysis of tumors resected for TIL. J Immunother 33:840–847CrossRefPubMed

Goldoni S, Iozzo RV (2008) Tumor microenvironment: modulation by decorin and related molecules harboring leucine-rich tandem motifs. Int J Cancer 123:2473–2479CrossRefPubMed

Grimm EA, Mazumder A, Zhang HZ, Rosenberg SA (1982) Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes. J Exp Med 155:1823–1841CrossRefPubMed

Han EQ, Li XL, Wang CR, Li TF, Han SY (2013) Chimeric antigen receptor-engineered T cells for cancer immunotherapy: progress and challenges. J Hematol Oncol 6:47CrossRefPubMedCentralPubMed

Hanagiri T, Shigematsu Y, Kuroda K, Baba T, Shiota H, Ichiki Y, Nagata Y, Yasuda M, So T, Takenoyama M, Tanaka F (2012) Antitumor activity of human gammadelta T cells transducted with CD8 and with T-cell receptors of tumor-specific cytotoxic T lymphocytes. Cancer Sci 103:1414–1419CrossRefPubMed

Horne ZD, Jack R, Gray ZT, Siegfried JM, Wilson DO, Yousem SA, Nason KS, Landreneau RJ, Luketich JD, Schuchert MJ (2011) Increased levels of tumor-infiltrating lymphocytes are associated with improved recurrence-free survival in stage 1A non-small-cell lung cancer. J Surg Res 171:1–5CrossRefPubMed

Jin CG, Chen XQ, Li J, Wu ZP, Liu X, Wang XC (2013) Moderating effects and maintenance of lung cancer cellular immune functions by CIK cell therapy. Asian Pac J Cancer Prev 14:3587–3592CrossRefPubMed

Ju SA, Park SM, Lee YS, Bae JH, Yu R, An WG, Suh JH, Kim BS (2012) Administration of 6-gingerol greatly enhances the number of tumor-infiltrating lymphocytes in murine tumors. Int J Cancer 130:2618–2628CrossRefPubMed

Jusufovic E, Prnjavorac B, Iljazovic E, Kosnik M, Keser D, Korosec P, Stahov J, Zukic E, Sejdinovic R, Ajanovic E (2011) Local CD4+, CD8+ and CD56+ T-lymphocite reaction on primary lung cancer. Acta Inform Med 19:132–137CrossRefPubMedCentralPubMed

Kalos M, Levine BL, Porter DL, Katz S, Grupp SA, Bagg A, June CH (2011) T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med 3:95ra73CrossRefPubMedCentralPubMed

Kataki A, Scheid P, Piet M, Marie B, Martinet N, Martinet Y, Vignaud JM (2002) Tumor infiltrating lymphocytes and macrophages have a potential dual role in lung cancer by supporting both host-defense and tumor progression. J Lab Clin Med 140:320–328CrossRefPubMed

Kato M, Goto S, Soma G (2010) Lymphokine-activated killer cell therapy combined with high-dose glucocorticoid showed clinical efficacy towards advanced lung carcinoma. Anticancer Res 30:3125–3128PubMed

Kawai O, Ishii G, Kubota K, Murata Y, Naito Y, Mizuno T, Aokage K, Saijo N, Nishiwaki Y, Gemma A, Kudoh S, Ochiai A (2008) Predominant infiltration of macrophages and CD8(+) T Cells in cancer nests is a significant predictor of survival in stage IV nonsmall cell lung cancer. Cancer 113:1387–1395CrossRefPubMed

Kilic A, Landreneau RJ, Luketich JD, Pennathur A, Schuchert MJ (2011) Density of tumor-infiltrating lymphocytes correlates with disease recurrence and survival in patients with large non-small-cell lung cancer tumors. J Surg Res 167:207–210CrossRefPubMed

Kimura H, Yamaguchi Y (1995) Adjuvant immunotherapy with interleukin 2 and lymphokine-activated killer cells after noncurative resection of primary lung cancer. Lung Cancer 13:31–44CrossRefPubMed

Kimura H, Yamaguchi Y (1997) A phase III randomized study of interleukin-2 lymphokine-activated killer cell immunotherapy combined with chemotherapy or radiotherapy after curative or noncurative resection of primary lung carcinoma. Cancer 80:42–49CrossRefPubMed

Lee SH, Cekanova M, Baek SJ (2008) Multiple mechanisms are involved in 6-gingerol-induced cell growth arrest and apoptosis in human colorectal cancer cells. Mol Carcinog 47:197–208CrossRefPubMedCentralPubMed

Li Z (2013) Potential of human gammadelta T cells for immunotherapy of osteosarcoma. Mol Biol Rep 40:427–437CrossRefPubMed

Li H, Wang C, Yu J, Cao S, Wei F, Zhang W, Han Y, Ren XB (2009) Dendritic cell-activated cytokine-induced killer cells enhance the anti-tumor effect of chemotherapy on non-small cell lung cancer in patients after surgery. Cytotherapy 11:1076–1083CrossRefPubMed

Li R, Wang C, Liu L, Du C, Cao S, Yu J, Wang SE, Hao X, Ren X, Li H (2012) Autologous cytokine-induced killer cell immunotherapy in lung cancer: a phase II clinical study. Cancer Immunol Immunother 61:2125–2133CrossRefPubMed

Lin CB, Lin CC, Tsay GJ (2012) 6-Gingerol inhibits growth of colon cancer cell LoVo via induction of G2/M arrest. Evid Based Complement Altern Med 2012:326096

Liu X, Li D, Zhang C, Ba D, Liu J, Wan T, Li Z, Jin Y, He Y (1993) Treatment of 121 patients with malignant effusion due to advanced lung cancer by intrapleural transfer of autologous or allogeneic LAK cells combined with rIL-2. Chin Med Sci J 8:186–189PubMed

Lv L, Chen H, Soroka D, Chen X, Leung T, Sang S (2012) 6-gingerdiols as the major metabolites of 6-gingerol in cancer cells and in mice and their cytotoxic effects on human cancer cells. J Agric Food Chem 60:11372–11377CrossRefPubMedCentralPubMed

Melioli G, Ratto GB, Ponte M, Guastella M, Semino C, Fantino G, Tassara E, Pasquetti W, Mereu C, Merlo F, Reggiardo G, Morasso G, Santi L, Moretta L (1996) Treatment of stage IIIB non-small-cell lung cancer with surgery followed by infusion of tumor infiltrating lymphocytes and recombinant interleukin-2: a pilot study. J Immunother Emphas Tumor Immunol 19:224–230CrossRef

Morgan RA, Dudley ME, Wunderlich JR, Hughes MS, Yang JC, Sherry RM, Royal RE, Topalian SL, Kammula US, Restifo NP, Zheng Z, Nahvi A, de Vries CR, Rogers-Freezer LJ, Mavroukakis SA, Rosenberg SA (2006) Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 314:126–129CrossRefPubMedCentralPubMed

Motohashi S, Ishikawa A, Ishikawa E, Otsuji M, Iizasa T, Hanaoka H, Shimizu N, Horiguchi S, Okamoto Y, Fujii S, Taniguchi M, Fujisawa T, Nakayama T (2006) A phase I study of in vitro expanded natural killer T cells in patients with advanced and recurrent non-small cell lung cancer. Clin Cancer Res 12:6079–6086CrossRefPubMed

Motohashi S, Nagato K, Kunii N, Yamamoto H, Yamasaki K, Okita K, Hanaoka H, Shimizu N, Suzuki M, Yoshino I, Taniguchi M, Fujisawa T, Nakayama T (2009) A phase I-II study of alpha-galactosylceramide-pulsed IL-2/GM-CSF-cultured peripheral blood mononuclear cells in patients with advanced and recurrent non-small cell lung cancer. J Immunol 182:2492–2501CrossRefPubMed

Motohashi S, Okamoto Y, Yoshino I, Nakayama T (2011) Anti-tumor immune responses induced by iNKT cell-based immunotherapy for lung cancer and head and neck cancer. Clin Immunol 140:167–176CrossRefPubMed

Nagato K, Motohashi S, Ishibashi F, Okita K, Yamasaki K, Moriya Y, Hoshino H, Yoshida S, Hanaoka H, Fujii S, Taniguchi M, Yoshino I, Nakayama T (2012) Accumulation of activated invariant natural killer T cells in the tumor microenvironment after alpha-galactosylceramide-pulsed antigen presenting cells. J Clin Immunol 32:1071–1081CrossRefPubMed

Nakajima J, Murakawa T, Fukami T, Goto S, Kaneko T, Yoshida Y, Takamoto S, Kakimi K (2010) A phase I study of adoptive immunotherapy for recurrent non-small-cell lung cancer patients with autologous gammadelta T cells. Eur J Cardiothorac Surg 37:1191–1197CrossRefPubMed

Pirker R, Pereira JR, Szczesna A, von Pawel J, Krzakowski M, Ramlau R, Vynnychenko I, Park K, Yu CT, Ganul V, Roh JK, Bajetta E, O’Byrne K, de Marinis F, Eberhardt W, Goddemeier T, Emig M, Gatzemeier U (2009) Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet 373:1525–1531CrossRefPubMed

Polo V, Besse B (2013) Maintenance strategies in stage IV non-small-cell lung cancer (NSCLC): in which patients, with which drugs? Ann Oncol 25:1283–1293

Ratto GB, Zino P, Mirabelli S, Minuti P, Aquilina R, Fantino G, Spessa E, Ponte M, Bruzzi P, Melioli G (1996) A randomized trial of adoptive immunotherapy with tumor-infiltrating lymphocytes and interleukin-2 versus standard therapy in the postoperative treatment of resected nonsmall cell lung carcinoma. Cancer 78:244–251CrossRefPubMed

Rosenberg SA, Yang JC, Topalian SL, Schwartzentruber DJ, Weber JS, Parkinson DR, Seipp CA, Einhorn JH, White DE (1994) Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. JAMA 271:907–913CrossRefPubMed

Russell RG (2011) Bisphosphonates: the first 40 years. Bone 49:2–19CrossRefPubMed

Sakamoto M, Nakajima J, Murakawa T, Fukami T, Yoshida Y, Murayama T, Takamoto S, Matsushita H, Kakimi K (2011) Adoptive immunotherapy for advanced non-small cell lung cancer using zoledronate-expanded gammadelta T cells: a phase I clinical study. J Immunother 34:202–211CrossRefPubMed

Satta A, Mezzanzanica D, Turatti F, Canevari S, Figini M (2013) Redirection of T-cell effector functions for cancer therapy: bispecific antibodies and chimeric antigen receptors. Future Oncol (London, England) 9:527–539CrossRef

Shi SB, Ma TH, Li CH, Tang XY (2012) Effect of maintenance therapy with dendritic cells: cytokine-induced killer cells in patients with advanced non-small cell lung cancer. Tumori 98:314–319PubMed

Shi S, Wang R, Chen Y, Song H, Chen L, Huang G (2013) Combining antiangiogenic therapy with adoptive cell immunotherapy exerts better antitumor effects in non-small cell lung cancer models. PLoS One 8:e65757CrossRefPubMedCentralPubMed

Siegel R, Naishadham D, Jemal A (2013) Cancer statistics, 2013. CA Cancer J Clin 63:11–30CrossRefPubMed

Takahashi K, Sone S, Saito S, Kamamura Y, Uyama T, Ogura T, Monden Y (1995) Granulocyte-macrophage colony-stimulating factor augments lymphokine-activated killer activity from pleural cavity mononuclear cells of lung cancer patients without malignant effusion. Jpn J Cancer Res 86:861–866CrossRefPubMed

Tan Y, Xu M, Wang W, Zhang F, Li D, Xu X, Gu J, Hoffman RM (1996) IL-2 gene therapy of advanced lung cancer patients. Anticancer Res 16:1993–1998PubMed

Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB, Leming PD, Spigel DR, Antonia SJ, Horn L, Drake CG, Pardoll DM, Chen L, Sharfman WH, Anders RA, Taube JM, McMiller TL, Xu H, Korman AJ, Jure-Kunkel M, Agrawal S, McDonald D, Kollia GD, Gupta A, Wigginton JM, Sznol M (2012) Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366:2443–2454CrossRefPubMedCentralPubMed

Viey E, Fromont G, Escudier B, Morel Y, Da Rocha S, Chouaib S, Caignard A (2005) Phosphostim-activated gamma delta T cells kill autologous metastatic renal cell carcinoma. J Immunol 174:1338–1347CrossRefPubMed

Wu C, Jiang J, Shi L, Xu N (2008) Prospective study of chemotherapy in combination with cytokine-induced killer cells in patients suffering from advanced non-small cell lung cancer. Anticancer Res 28:3997–4002PubMed

Yamamoto K, Trad A, Baumgart A, Huske L, Lorenzen I, Chalaris A, Grotzinger J, Dechow T, Scheller J, Rose-John S (2012) A novel bispecific single-chain antibody for ADAM17 and CD3 induces T-cell-mediated lysis of prostate cancer cells. Biochem J 445:135–144CrossRefPubMed

Yang L, Ren B, Li H, Yu J, Cao S, Hao X, Ren X (2013) Enhanced antitumor effects of DC-activated CIKs to chemotherapy treatment in a single cohort of advanced non-small-cell lung cancer patients. Cancer Immunol Immunother 62:65–73CrossRefPubMed

Yano T, Sugio K, Yamazaki K, Kase S, Yamaguchi M, Ondo K, Yoshino I, Sugimachi K (1999) Postoperative adjuvant adoptive immunotherapy with lymph node-LAK cells and IL-2 for pathologic stage I non-small cell lung cancer. Lung Cancer 26:143–148CrossRefPubMed

Yoshida Y, Nakajima J, Wada H, Kakimi K (2011) gammadelta T-cell immunotherapy for lung cancer. Surg Today 41:606–611CrossRefPubMed

Yuanying Y, Lizhi N, Feng M, Xiaohua W, Jianying Z, Fei Y, Feng J, Lihua H, Jibing C, Jialiang L, Kecheng X (2013) Therapeutic outcomes of combining cryotherapy, chemotherapy and DC-CIK immunotherapy in the treatment of metastatic non-small cell lung cancer. Cryobiology 67:235–240CrossRefPubMed

Zhang G, Chen S, Goldoni S, Calder BW, Simpson HC, Owens RT, McQuillan DJ, Young MF, Iozzo RV, Birk DE (2009) Genetic evidence for the coordinated regulation of collagen fibrillogenesis in the cornea by decorin and biglycan. J Biol Chem 284:8888–8897CrossRefPubMedCentralPubMed

Zhang Q, Li H, Yang J, Li L, Zhang B, Li J, Zheng J (2013) Strategies to improve the clinical performance of chimeric antigen receptor-modified T cells for cancer. Curr Gene Ther 13:65–70CrossRefPubMed

Zhao H, Xi X, Cui L, He W (2012) CDR3delta-grafted gamma9delta2T cells mediate effective antitumor reactivity. Cell Mol Immunol 9:147–154CrossRefPubMedCentralPubMed

Zhong R, Teng J, Han B, Zhong H (2011) Dendritic cells combining with cytokine-induced killer cells synergize chemotherapy in patients with late-stage non-small cell lung cancer. Cancer Immunol Immunother 60:1497–1502CrossRefPubMed

Zhong R, Han B, Zhong H (2014) A prospective study of the efficacy of a combination of autologous dendritic cells, cytokine-induced killer cells, and chemotherapy in advanced non-small cell lung cancer patients. Tumour Biol 35:987–994CrossRefPubMed

Titel: T-cell-associated cellular immunotherapy for lung cancer
verfasst von: Ke Li
Qing Zhang
Yang Zhang
Jie Yang
Junnian Zheng
Publikationsdatum: 01.07.2015
Verlag: Springer Berlin Heidelberg
Erschienen in: Journal of Cancer Research and Clinical Oncology / Ausgabe 7/2015
Print ISSN: 0171-5216
Elektronische ISSN: 1432-1335
DOI: https://doi.org/10.1007/s00432-014-1867-0

Neu im Fachgebiet Onkologie

25.04.2024 | Nierenkarzinom | Nachrichten

Springer Medizin

T-cell-associated cellular immunotherapy for lung cancer

Abstract

Purpose

Methods

Results

Conclusions

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 7/2015

Stomach cancer mortality among workers exposed to asbestos: a meta-analysis

Detection of relapse after hematopoietic stem cell transplantation in childhood by monitoring of WT1 expression and chimerism

A tumor-specific microRNA signature predicts survival in clear cell renal cell carcinoma

Systematic evaluation of cancer risk associated with DNMT3B polymorphisms

The challenge of inoperable hepatocellular carcinoma (HCC): results of a single-institutional experience on stereotactic body radiation therapy (SBRT)

Bile acid induces MUC2 expression and inhibits tumor invasion in gastric carcinomas

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie